ATE150000T1 - Einfluss von n,n,n-trimethylsphingosin auf die aktivität der protein-c-kinase, melanomzellwachstum in vitro, metastatisches potential in vivo und humane blutblättchenaggregation - Google Patents

Einfluss von n,n,n-trimethylsphingosin auf die aktivität der protein-c-kinase, melanomzellwachstum in vitro, metastatisches potential in vivo und humane blutblättchenaggregation

Info

Publication number: ATE150000T1
Authority: AT; Austria
Prior art keywords: pct; trimethylsphingosine; kinase; vitro; vivo
Prior art date: 1990-12-31

Application number

AT92902672T

Other languages

English (en)

Inventor

Satoshi Kimura

Yasyuki Igarashi

Sen-Itiroh Hakomori

Mahammed N Ahmad

Hirofumi Okoshi

Kazuko Handa

Original Assignee

Oncomembrane Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-12-31

Filing date

1991-12-23

Publication date

1997-03-15

1990-12-31 Priority claimed from US07/636,353 external-priority patent/US5137919A/en

1991-12-23 Application filed by Oncomembrane Inc filed Critical Oncomembrane Inc

1997-03-15 Application granted granted Critical

1997-03-15 Publication of ATE150000T1 publication Critical patent/ATE150000T1/de

Links

HPUYQTKUQJNJQO-IAYMVZNDSA-N [(e,2s,3r)-1,3-dihydroxyoct-4-en-2-yl]-trimethylazanium Chemical compound CCC\C=C\[C@@H](O)[C@H](CO)[N+](C)(C)C HPUYQTKUQJNJQO-IAYMVZNDSA-N 0.000 title abstract 2
230000001394 metastastic effect Effects 0.000 title abstract 2
241000282414 Homo sapiens Species 0.000 title 1
102000001253 Protein Kinase Human genes 0.000 title 1
230000002776 aggregation Effects 0.000 title 1
238000004220 aggregation Methods 0.000 title 1
230000010261 cell growth Effects 0.000 title 1
230000000694 effects Effects 0.000 title 1
238000000338 in vitro Methods 0.000 title 1
201000001441 melanoma Diseases 0.000 title 1
206010061289 metastatic neoplasm Diseases 0.000 title 1
108060006633 protein kinase Proteins 0.000 title 1
102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
230000002401 inhibitory effect Effects 0.000 abstract 3
230000004663 cell proliferation Effects 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
108010067225 Cell Adhesion Molecules Proteins 0.000 abstract 1
230000002001 anti-metastasis Effects 0.000 abstract 1
102000008395 cell adhesion mediator activity proteins Human genes 0.000 abstract 1
230000003211 malignant effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
210000004881 tumor cell Anatomy 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT92902672T 1990-12-31 1991-12-23 Einfluss von n,n,n-trimethylsphingosin auf die aktivität der protein-c-kinase, melanomzellwachstum in vitro, metastatisches potential in vivo und humane blutblättchenaggregation ATE150000T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US07/636,353 US5137919A (en)	1990-12-31	1990-12-31	Effect of N,N,N,-trimethylsphingosine on protein kinase C activity melanoma cell growth in vitro; metastatic potential in vivo and human platelet aggregation
US07/724,625 US5151360A (en)	1990-12-31	1991-07-02	Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation

Publications (1)

Publication Number	Publication Date
ATE150000T1 true ATE150000T1 (de)	1997-03-15

Family

ID=27092583

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92902672T ATE150000T1 (de)	1990-12-31	1991-12-23	Einfluss von n,n,n-trimethylsphingosin auf die aktivität der protein-c-kinase, melanomzellwachstum in vitro, metastatisches potential in vivo und humane blutblättchenaggregation

Country Status (10)

Country	Link
US (2)	US5151360A (de)
EP (1)	EP0565587B1 (de)
JP (1)	JPH06504052A (de)
AT (1)	ATE150000T1 (de)
CA (1)	CA2097324A1 (de)
DE (1)	DE69125185T2 (de)
DK (1)	DK0565587T3 (de)
ES (1)	ES2100333T3 (de)
GR (1)	GR3023511T3 (de)
WO (1)	WO1992012119A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5583160A (en) *	1989-02-03	1996-12-10	The Biomembrane Institute	Methylsphingosine used to treat apoptosis
US5466716A (en) *	1990-12-31	1995-11-14	The Biomembrane Institute	Liposomal trimethylsphingosine
DE69333924T2 (de) *	1992-05-29	2006-08-17	University Of North Carolina At Chapel Hill	Im immobilisierten Zustand getrocknete pharmazeutisch verträgliche menschliche Blutplättchen
US5321012A (en) *	1993-01-28	1994-06-14	Virginia Commonwealth University Medical College	Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
USRE39300E1 (en)	1993-01-28	2006-09-19	Virginia Commonwealth University Medical College Of Virginia	Inhibiting the development of tolerance to and/or dependence on an addictive substance
EP0724562B1 (de) *	1993-10-18	1998-06-03	Virginia Tech Intellectual Properties, Inc.	Synthese von sphingosinen
ATE232901T1 (de) *	1994-04-04	2003-03-15	Regeneron Pharma	Biologisch aktive ligande der eph familie
US5627171A (en) *	1994-04-11	1997-05-06	Oncomembrane, Inc.	Sphingosine-1-phosphate/trimethylsphingosine composition
US5587459A (en) *	1994-08-19	1996-12-24	Regents Of The University Of Minnesota	Immunoconjugates comprising tyrosine kinase inhibitors
EP0754053A1 (de) *	1995-02-03	1997-01-22	Korea Institute of Science and Technology	Neuartige blutstillende zusammensetzung
EP0888458A4 (de) *	1996-02-20	2004-05-06	Sloan Kettering Institutefor C	Kombination von pkc-inhibitoren und therapeutischen agenzien zur behandlung von krebs
GB9620390D0 (en) *	1996-09-30	1996-11-13	Eisai London Res Lab Ltd	Substances and their uses
WO1998055602A1 (en) *	1997-06-06	1998-12-10	Mayo Foundation For Medical Education And Research	Screening for phosphatidylinositol related-kinase inhibitors
US6649362B2 (en) *	1997-09-08	2003-11-18	Medvet Science Pty. Ltd.	Screening method for an agent having an effect on a sphingosine kinase signaling pathway
US6098631A (en) *	1998-01-21	2000-08-08	The Regents Of The University Of Michigan	Compositions and methods for treating autoimmune disease
US6770478B2 (en)	2000-02-10	2004-08-03	The Regents Of The University Of California	Erythrocytic cells and method for preserving cells
CA2397362A1 (en) *	2000-02-10	2001-08-16	The Regents Of The University Of California	Therapeutic platelets and methods
US20030028018A1 (en) *	2000-09-11	2003-02-06	Chiron Coporation	Quinolinone derivatives
DE60115069T2 (de) *	2000-09-11	2006-08-03	Chiron Corp., Emeryville	Chinolinonderivate als tyrosin-kinase inhibitoren
CA2432978C (en) *	2000-12-22	2012-08-28	Medlyte, Inc.	Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
WO2003086377A1 (en) *	2002-04-18	2003-10-23	Institute Of Medicinal Molecular Design. Inc.	Amide derivatives
WO2003097658A2 (en)	2002-05-16	2003-11-27	Glycomimetics, Inc.	Compounds and methods for inhibiting selectin-mediated function
JP2006502986A (ja) *	2002-07-03	2006-01-26	グリコミメティクス，インコーポレイテッド	新脈管形成に関与する医学的状態の診断および治療のための組成物および方法
EP1539754A4 (de) *	2002-08-23	2009-02-25	Novartis Vaccines & Diagnostic	Benzimidazolchinolinone und deren verwendung
US7825132B2 (en) *	2002-08-23	2010-11-02	Novartis Vaccines And Diagnostics, Inc.	Inhibition of FGFR3 and treatment of multiple myeloma
US20050256157A1 (en) *	2002-08-23	2005-11-17	Chiron Corporation	Combination therapy with CHK1 inhibitors
SG148864A1 (en) *	2002-11-13	2009-01-29	Chiron Corp	Methods of treating cancer and related methods
US20040219158A1 (en) *	2003-05-02	2004-11-04	Glycomimetics, Inc.	Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
US20050209247A1 (en) *	2003-11-07	2005-09-22	Chiron Corporation	Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
EP1763533B1 (de) *	2003-11-19	2008-01-09	GlycoMimetics, Inc.	Spezifischer antagonist sowohl für e- als auch p-selektine
WO2005054264A2 (en) *	2003-11-19	2005-06-16	Glycomimetics, Inc.	Glycomimetic antagonists for both e- and p-selectins
EP1718306A2 (de) *	2004-02-20	2006-11-08	Chiron Corporation	Modulation von entzündlichen und metastatischen prozessen
US7794713B2 (en) *	2004-04-07	2010-09-14	Lpath, Inc.	Compositions and methods for the treatment and prevention of hyperproliferative diseases
US8143254B2 (en) *	2005-02-18	2012-03-27	Cornell Research Foundation, Inc.	Methods for modulating ion channels
EP1885187B1 (de)	2005-05-13	2013-09-25	Novartis AG	Verfahren zur behandlung von arzneimittelresistentem krebs
BRPI0611375A2 (pt) *	2005-05-23	2010-08-31	Novartis Ag	formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
US20090036386A1 (en) *	2005-05-25	2009-02-05	Glycomimetics, Inc	Heterobifunctional compounds for selectin inhibition
CN101291946B (zh) *	2005-08-09	2011-06-29	糖模拟物有限公司	对来自假单胞菌的pa-il凝集素、pa-iil凝集素或其两者的糖模拟物抑制剂
PL2264043T3 (pl) *	2005-09-02	2018-04-30	Glycomimetics, Inc.	Heterobifunkcyjne inhibitory pan-selektyny
US7862812B2 (en)	2006-05-31	2011-01-04	Lpath, Inc.	Methods for decreasing immune response and treating immune conditions
US9217749B2 (en) *	2006-05-31	2015-12-22	Lpath, Inc.	Immune-derived moieties reactive against lysophosphatidic acid
US8796429B2 (en) *	2006-05-31	2014-08-05	Lpath, Inc.	Bioactive lipid derivatives, and methods of making and using same
US9274130B2 (en)	2006-05-31	2016-03-01	Lpath, Inc.	Prevention and treatment of pain using antibodies to lysophosphatidic acid
US9274129B2 (en) *	2006-05-31	2016-03-01	Lpath, Inc.	Methods and reagents for detecting bioactive lipids
US20090176717A1 (en) *	2006-06-01	2009-07-09	Glycomimetics, Inc.	Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
EP2074132B1 (de) *	2006-10-12	2013-05-15	GlycoMimetics, Inc.	Glycomimetischer ersatz für hexosen und n-acetyl-hexosamine
PL2087002T3 (pl)	2006-10-27	2015-02-27	Lpath Inc	Kompozycje i sposoby do wiązania sfingozyno-1 fosforanu
US8614103B2 (en) *	2006-10-27	2013-12-24	Lpath, Inc.	Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions
AU2008216794A1 (en) *	2007-02-09	2008-08-21	Glycomimetics, Inc.	Methods of use of glycomimetics with replacements for hexoses and N-acetyl hexosamines
DE102007008484A1 (de) *	2007-02-19	2008-08-21	Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh	Pharmazeutische Zubereitung zur Bekämpfung von Metastasen
US8039442B2 (en)	2007-07-18	2011-10-18	Glycomimetics, Inc.	Compounds and methods for treatment of sickle cell disease or complications associated therewith
US8361465B2 (en) *	2007-10-26	2013-01-29	Lpath, Inc.	Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
WO2009126556A1 (en)	2008-04-08	2009-10-15	Glycomimetics, Inc.	Pan-selectin inhibitor with enhanced pharmacokinetic activity
CN102088983B (zh) *	2008-06-13	2013-01-30	糖模拟物有限公司	利用选择的糖模拟化合物的血液癌症的治疗
US8871202B2 (en)	2008-10-24	2014-10-28	Lpath, Inc.	Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
CA2760292A1 (en) *	2009-05-01	2010-11-04	Glycomimetics, Inc.	Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
EP2462105A1 (de) *	2009-08-04	2012-06-13	Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.	Amino-alkohol-analoga und ihre verwendung
JP2013533286A (ja)	2010-07-30	2013-08-22	セントルイスユニバーシティ	疼痛を治療する方法
US8921328B2 (en)	2010-09-14	2014-12-30	Glycomimetics, Inc.	E-selectin antagonists
KR102055958B1 (ko)	2011-12-22	2019-12-13	글리코미메틱스, 인크.	E-셀렉틴 길항제 화합물, 조성물, 및 이용 방법
US9867841B2 (en)	2012-12-07	2018-01-16	Glycomimetics, Inc.	Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
ES2851724T3 (es)	2013-09-18	2021-09-08	Epiaxis Therapeutics Pty Ltd	Modulación de células madre
JP6689854B2 (ja)	2014-12-03	2020-04-28	グリコミメティクス，インコーポレイテッド	Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤
WO2017015334A1 (en)	2015-07-21	2017-01-26	Saint Louis University	Compositions and methods for diagnosing and treating endometriosis-related infertility
JP2019502727A (ja)	2016-01-22	2019-01-31	グリコミメティクス，インコーポレイテッド	Ｐａ−ｉｌおよび／またはｐａ−ｉｉｌレクチンの糖模倣体阻害剤
WO2017151708A1 (en)	2016-03-02	2017-09-08	Glycomimetics, Inc.	Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
US11433086B2 (en)	2016-08-08	2022-09-06	Glycomimetics, Inc.	Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
AU2017341065B2 (en)	2016-10-07	2023-04-06	Crescent Biopharma, Inc.	Highly potent multimeric E-selectin antagonists
EP3596096A1 (de)	2017-03-15	2020-01-22	GlycoMimetics, Inc.	Galactopyranosyl-cyclohexyl-derivate als e-selectin-antagonisten
JP7275131B2 (ja)	2017-11-30	2023-05-17	グリコミメティクス，インコーポレイテッド	骨髄浸潤リンパ球を動員する方法、およびその使用
KR20200104889A (ko)	2017-12-29	2020-09-04	글리코미메틱스, 인크.	E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제
KR20200128025A (ko)	2018-03-05	2020-11-11	글리코미메틱스, 인크.	급성 골수성 백혈병 및 관련 병태의 치료 방법
US11845771B2 (en)	2018-12-27	2023-12-19	Glycomimetics, Inc.	Heterobifunctional inhibitors of E-selectin and galectin-3

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3705384A1 (de) *	1987-02-20	1988-09-01	Goedecke Ag	2-propylamin-derivate, verfahren zu deren herstellung sowie deren verwendung
CA2007507C (en) *	1989-02-03	1998-05-19	Yasuyuki Igarashi	Sphingosine and n-methyl-sphingosine as inhibitor of cell growth

1991
- 1991-07-02 US US07/724,625 patent/US5151360A/en not_active Expired - Lifetime
- 1991-12-23 DE DE69125185T patent/DE69125185T2/de not_active Expired - Fee Related
- 1991-12-23 JP JP4502850A patent/JPH06504052A/ja active Pending
- 1991-12-23 EP EP92902672A patent/EP0565587B1/de not_active Expired - Lifetime
- 1991-12-23 AT AT92902672T patent/ATE150000T1/de not_active IP Right Cessation
- 1991-12-23 DK DK92902672.2T patent/DK0565587T3/da active
- 1991-12-23 US US08/081,383 patent/US5331014A/en not_active Expired - Fee Related
- 1991-12-23 ES ES92902672T patent/ES2100333T3/es not_active Expired - Lifetime
- 1991-12-23 CA CA002097324A patent/CA2097324A1/en not_active Abandoned
- 1991-12-23 WO PCT/US1991/009196 patent/WO1992012119A1/en not_active Ceased
1997
- 1997-05-22 GR GR970401158T patent/GR3023511T3/el unknown

Also Published As

Publication number	Publication date
US5331014A (en)	1994-07-19
US5151360A (en)	1992-09-29
CA2097324A1 (en)	1992-07-01
ES2100333T3 (es)	1997-06-16
GR3023511T3 (en)	1997-08-29
JPH06504052A (ja)	1994-05-12
EP0565587A1 (de)	1993-10-20
DE69125185D1 (de)	1997-04-17
DE69125185T2 (de)	1997-08-28
DK0565587T3 (da)	1997-09-22
WO1992012119A1 (en)	1992-07-23
EP0565587A4 (en)	1994-06-01
EP0565587B1 (de)	1997-03-12

Legal Events

Date	Code	Title	Description
1997-09-15	UEP	Publication of translation of european patent specification
2004-09-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE150000T1 (de)	1997-03-15	Einfluss von n,n,n-trimethylsphingosin auf die aktivität der protein-c-kinase, melanomzellwachstum in vitro, metastatisches potential in vivo und humane blutblättchenaggregation
GEP20032954B (en)	2003-04-25	Heterocyclic Inhibitors of P38
ATE296799T1 (de)	2005-06-15	P38-inhibitoren
ATE202785T1 (de)	2001-07-15	Verbindungen mit wachstumshormon-freisetzenden eigenschaften
ATE529109T1 (de)	2011-11-15	Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
TR200100917T2 (tr)	2001-07-23	Aril ve heteroaril sübstitüentli heteroksiklik üreler kullanılarak RAF kinazın inhibe edilmesi
BR9611175B1 (pt)	2009-01-13	compostos e composiÇÕes farmacÊuticas.
TR199902194T2 (xx)	2000-06-21	+p38 protein kinaz inhibit�rleri olarak ikameli azot ihtiva eden heterosikler.
DE69836563D1 (de)	2007-01-11	INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYLSUBSTITUIERTEN HARNSTOFFEN
ATE185548T1 (de)	1999-10-15	Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
IL81002A (en)	1991-07-18	3,4-diphenyl-pyrazoline-1-carboxamide derivatives,processes for the preparation thereof and insecticidal and acaricidal compositions containing the same
DE59915127D1 (de)	2010-03-11	Imidazolidinderivate, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
BG103399A (en)	2000-01-31	New heterocycle-substituted benzamides and their application for the treatment of diseases
YU13396A (sh)	1999-06-15	N-(3-benzofuranil) urea derivati, postupci za njihovo dobijanje, kompozicije koje ih sadrže i njihova upotreba u lekovima
BG103219A (bg)	1999-10-29	Бензамидинови производни и използването им като лекарствени средства с ltb4-антагонистично действие
GEP19971265B (en)	1997-12-01	Substituted sulphonamides,, the substituted cyclic amines in the form of intermediate compounds for reception of the substituted sulphonamides and the pharmaceutical composition on the basis of the substituted sulphonamides displaying activity towards thromboxane receptors
ATE181063T1 (de)	1999-06-15	Vitamin-d-amid derivate
IT1277391B1 (it)	1997-11-10	Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita
IT1216104B (it)	1990-02-22	Peptidi ad attivita' farmaceutica.
DE69421531D1 (de)	1999-12-09	Verwendung von rosmanolderivaten zur herstellung von antiradikalischen und/oder antilipoperoxidativen und/oder hepatotropen arzneistoffen
MY107258A (en)	1995-10-31	1-methoxypyrimidinyl-n-nitrophenyl-1h-1,2,4-triazole-3- sulphonamides, processes for their preparation and their use as herbicides.
NO305519B1 (no)	1999-06-14	Benzo[f]kinoksalindionderivater og legemidler inneholdende disse
ATE36957T1 (de)	1988-09-15	N,n-diethyl-5-methyl-2h,1-benzothiopyrano-(4,3, - cd)-indazol-2-ethanamine, diese enthaltende zubereitungen und ihre verwendung.
IT1216103B (it)	1990-02-22	Peptidi ad attivita' farmaceutica.
MY101964A (en)	1992-12-15	Furo-(3,4-c)- pyridine derivatives